179 related articles for article (PubMed ID: 33628621)
1. A multicenter characterization of hepatitis associated with immune checkpoint inhibitors.
Patrinely JR; McGuigan B; Chandra S; Fenton SE; Chowdhary A; Kennedy LB; Mooradian MJ; Palmeri M; Portal D; Horst SN; Scoville EA; Long GV; Shi C; Mehnert JM; Sullivan RJ; Salama AK; Sosman JA; Menzies AM; Johnson DB
Oncoimmunology; 2021 Feb; 10(1):1875639. PubMed ID: 33628621
[TBL] [Abstract][Full Text] [Related]
2. Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis.
Li M; Sack JS; Rahma OE; Hodi FS; Zucker SD; Grover S
Cancer; 2020 Dec; 126(23):5088-5097. PubMed ID: 32888341
[TBL] [Abstract][Full Text] [Related]
3. Rare immune-related adverse events in patients with melanoma: incidence, spectrum, and clinical presentations.
Park BC; Narayanan S; Gavraldis A; Ye F; Fan R; Sullivan RJ; Boland G; Reynolds KL; Balko JM; Carlino MS; Long GV; Zubiri L; Menzies AM; Johnson DB
Oncoimmunology; 2023; 12(1):2188719. PubMed ID: 36926262
[TBL] [Abstract][Full Text] [Related]
4. Response to immune checkpoint inhibitor rechallenge after high-grade immune related adverse events in patients with advanced melanoma.
Shah P; Punekar SR; Pavlick AC
Melanoma Res; 2021 Jun; 31(3):242-248. PubMed ID: 33741813
[TBL] [Abstract][Full Text] [Related]
5. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
6. Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience.
Bhatlapenumarthi V; Patwari A; Harb AJ
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2789-2800. PubMed ID: 33774736
[TBL] [Abstract][Full Text] [Related]
7. Severe immune-related hepatitis induced by immune checkpoint inhibitors: Clinical features and management proposal.
Gauci ML; Baroudjian B; Bédérède U; Zeboulon C; Delyon J; Allayous C; Madelaine I; Eftekhari P; Resche-Rigon M; Poté N; Paradis V; Durand F; Lebbé C; Roux O; Bouattour M;
Clin Res Hepatol Gastroenterol; 2021 Mar; 45(2):101491. PubMed ID: 32773362
[TBL] [Abstract][Full Text] [Related]
8. Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer.
Allouchery M; Lombard T; Martin M; Rouby F; Sassier M; Bertin C; Atzenhoffer M; Miremont-Salame G; Perault-Pochat MC; Puyade M;
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428586
[TBL] [Abstract][Full Text] [Related]
9. Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients.
Purde MT; Niederer R; Wagner NB; Diem S; Berner F; Hasan Ali O; Hillmann D; Bergamin I; Joerger M; Risch M; Niederhauser C; Lenz TL; Früh M; Risch L; Semela D; Flatz L
J Cancer Res Clin Oncol; 2022 Mar; 148(3):647-656. PubMed ID: 34874490
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy.
Halle BR; Betof Warner A; Zaman FY; Haydon A; Bhave P; Dewan AK; Ye F; Irlmeier R; Mehta P; Kurtansky NR; Lacouture ME; Hassel JC; Choi JS; Sosman JA; Chandra S; Otto TS; Sullivan R; Mooradian MJ; Chen ST; Dimitriou F; Long G; Carlino M; Menzies A; Johnson DB; Rotemberg VM
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34635495
[TBL] [Abstract][Full Text] [Related]
11. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
Shankar B; Zhang J; Naqash AR; Forde PM; Feliciano JL; Marrone KA; Ettinger DS; Hann CL; Brahmer JR; Ricciuti B; Owen D; Toi Y; Walker P; Otterson GA; Patel SH; Sugawara S; Naidoo J
JAMA Oncol; 2020 Dec; 6(12):1952-1956. PubMed ID: 33119034
[TBL] [Abstract][Full Text] [Related]
12. Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG study.
Stege HM; Haist M; Schultheis S; Fleischer MI; Mohr P; Ugurel S; Terheyden P; Thiem A; Kiecker F; Leiter U; Becker JC; Meissner M; Kleeman J; Pföhler C; Hassel J; Grabbe S; Loquai C
Cancer Immunol Immunother; 2021 Nov; 70(11):3313-3322. PubMed ID: 33870464
[TBL] [Abstract][Full Text] [Related]
13. Retreatment With Immune Checkpoint Inhibitors After a Severe Immune-Related Hepatitis: Results From a Prospective Multicenter Study.
Riveiro-Barciela M; Barreira-Díaz A; Callejo-Pérez A; Muñoz-Couselo E; Díaz-Mejía N; Díaz-González Á; Londoño MC; Salcedo MT; Buti M
Clin Gastroenterol Hepatol; 2023 Mar; 21(3):732-740. PubMed ID: 35487453
[TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis.
Zhao Q; Zhang J; Xu L; Yang H; Liang N; Zhang L; Zhang F; Zhang X
Front Immunol; 2021; 12():730320. PubMed ID: 34646270
[TBL] [Abstract][Full Text] [Related]
15. Clinical Characteristics and Outcomes of Oral Mucositis Associated With Immune Checkpoint Inhibitors in Patients With Cancer.
Jacob JS; Dutra BE; Garcia-Rodriguez V; Panneerselvam K; Abraham FO; Zou F; Ma W; Grivas P; Thompson JA; Altan M; Oliva ICG; Zhang HC; Thomas AS; Wang Y
J Natl Compr Canc Netw; 2021 Aug; 19(12):1415-1424. PubMed ID: 34348238
[TBL] [Abstract][Full Text] [Related]
16. Immune-related adverse events are associated with improved response, progression-free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitors.
Foster CC; Couey MA; Kochanny SE; Khattri A; Acharya RK; Tan YC; Brisson RJ; Leidner RS; Seiwert TY
Cancer; 2021 Dec; 127(24):4565-4573. PubMed ID: 34547103
[TBL] [Abstract][Full Text] [Related]
17. Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy.
Ghisoni E; Wicky A; Bouchaab H; Imbimbo M; Delyon J; Gautron Moura B; Gérard CL; Latifyan S; Özdemir BC; Caikovski M; Pradervand S; Tavazzi E; Gatta R; Marandino L; Valabrega G; Aglietta M; Obeid M; Homicsko K; Mederos Alfonso NN; Zimmermann S; Coukos G; Peters S; Cuendet MA; Di Maio M; Michielin O
Eur J Cancer; 2021 May; 149():153-164. PubMed ID: 33865201
[TBL] [Abstract][Full Text] [Related]
18. Effects of immune checkpoint inhibitor therapy resumption in patients with malignant tumors after moderate-to-severe immune-related adverse events.
Kawahira M; Kanmura S; Mizuno K; Machida K; Ohtsuka T; Sato M; Enokida H; Yamashita M; Kanekura T; Arima S; Nakamura N; Sugiura T; Yoshimoto K; Kobayashi H; Ishitsuka K; Suzuki S; Ueno S; Ido A
PLoS One; 2022; 17(4):e0267572. PubMed ID: 35482642
[TBL] [Abstract][Full Text] [Related]
19. Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival.
Yamada K; Sawada T; Nakamura M; Yamamura T; Maeda K; Ishikawa E; Iida T; Mizutani Y; Kakushima N; Ishikawa T; Furukawa K; Ohno E; Honda T; Kawashima H; Ishigami M; Furune S; Hase T; Yokota K; Maeda O; Hashimoto N; Akiyama M; Ando Y; Fujishiro M
World J Gastroenterol; 2021 Nov; 27(41):7190-7206. PubMed ID: 34887637
[TBL] [Abstract][Full Text] [Related]
20. Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events.
Siddiqui BA; Gheeya JS; Goswamy R; Bathala TK; Surasi DS; Gao J; Shah A; Campbell MT; Msaouel P; Goswami S; Wang J; Zurita AJ; Jonasch E; Corn PG; Aparicio AM; Siefker-Radtke AO; Sharma P; Subudhi SK; Tannir N
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]